ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Human Genome Consortium Completes “Working Draft”.

June 30, 2000

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

In Brief: Cancer Panel To Meet Aug.29; RFP On Impact Of Planning Cancelled As Being “Premature“

August 15, 1980

FDA Proposes New Nonclinical Lab Regs

November 26, 1976

DCBD Board Okays Concept Of Program Announcement To Stimulate Human Monoclonal Antibody Research

June 4, 1982

Community Oncology Alliance Attack On Republican Leadership Prompts Others To Declare: We Aren’t COA.

September 29, 2006